ScreenerHero

JSPR Jasper Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · jaspertx.com
0.5697USD+1.71%Mkt Cap: 18.96M $P/E: —

Jasper Therapeutics, Inc., a clinical stage biotechnology company, focuses on the design and development of therapies to treat immune-mediated diseases. It is advancing a pipeline of medicines, including KP-104, a dual-c…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap18.96M USD
Enterprise Value—
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-75.80M USD
Revenue/Share—
Last Price0.5697 USD
Fiscal Year End—
MR Quarter—
Employees—
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.22
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B11.20
EPS (TTM)-0.99
EPS (Forward)-2.56
52W Range
0.315111% of range2.690
52W High2.690 USD
52W Low0.3151 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-1826.09%
ROA-211.86%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-77.16M USD
CapEx (TTM)7.00K USD
FCF Margin—
FCF Yield—
Net Debt—
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.30
Current Ratio—
Quick Ratio—
Book Value/Sh0.05 USD
Cash/Share—
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateJan 4, 2024
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)20.00 USD
Upside (mean)+3410.6%
Target Range20.00 USD – 20.00 USD
# Analysts1
Ownership
Shares Out.33.27M
Float—
Insiders2.86%
Institutions39.27%
Short Interest
Short Ratio10.5d
Short % Float17.78%
Short % Out.17.46%
Shares Short5.81M
Short (prev mo.)5.36M
Technical
SMA 500.6766 (-15.8%)
SMA 2000.9699 (-41.3%)
Beta—
S&P 52W Chg16.45%
Avg Vol (30d)384.86K
Avg Vol (10d)414.64K
Technical Indicators
RSI (14)42.0
MACD-0.0306
MACD Signal-0.0280
MACD Hist.-0.0026
BB Upper0.7080 USD
BB Middle0.6148 USD
BB Lower0.5216 USD
BB Width30.33%
ATR (14)0.0645 USD
Vol Ratio (20d)1.02x